Impact of Substance Use Disorder on Presentation and Short-Term Course of Schizophrenia
Table 5
Resolution of symptom in schizophrenia patients with substance abuse (Group 1, ) and without substance abuse (Group 2, ): general linear model repeat measure ANOVA.
Variable
Group
Baseline
After 3 weeks
After 6 weeks
PANSS positive scale
Group 1
23.83 ± 6.41
17.00 ± 6.80
13.09 ± 5.84
0.766
0.454
Group 2
23.94 ± 6.19
16.71 ± 7.63
13.23 ± 5.86
PANSS negative scale
Group 1
26.21 ± 8.05
19.52 ± 7.97
16.10 ± 7.63
1.090
0.325
Group 2
26.46 ± 7.41
19.07 ± 7.25
14.98 ± 6.96
PANSS general scale
Group 1
44.01 ± 7.19
31.61 ± 7.86
25.84 ± 6.72
0.119
0.865
Group 2
45.23 ± 7.44
32.26 ± 8.67
26.61 ± 7.63
PANSS total
Group 1
93.95 ± 14.10
67.89 ± 17.95
54.82 ± 16.65
0.157
0.832
Group 2
95.55 ± 12.05
68.40 ± 18.07
55.16 ± 16.24
Calgary
Group 1
7.57 ± 7.77
3.70 ± 5.02
2.24 ± 4.58
1.391
0.249
Group 2
4.44 ± 5.63
2.13 ± 3.84
0.98 ± 2.53
HARS
Group 1
17.90 ± 8.74
10.43 ± 7.30
6.23 ± 6.89
0.013
0.980
Group 2
15.71 ± 7.48
9.15 ± 6.33
4.84 ± 5.01
BPRS
Group 1
33.93 ± 8.06
19.85 ± 9.77
12.45 ± 9.11
0.155
0.832
Group 2
34.71 ± 7.41
19.53 ± 10.49
12.17 ± 8.95
Mauchly’s test of sphericity sig.: 0.000; : Greenhouse-Geisser correction.
